Keywords: gilead, aztreonam, meets, ph, iii, endpoint, drugmaker

Gilead's aztreonam meets Ph III endpoint

Article | 22 December 2006

Print This

US drugmaker Gilead Sciences says that a Phase III study of its drug candidate aztreonam lysine for inhalation for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in